613 related articles for article (PubMed ID: 14700743)
1. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
Nielsen LL; Young AA; Parkes DG
Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
[TBL] [Abstract][Full Text] [Related]
2. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
Holz GG; Chepurny OG
Curr Med Chem; 2003 Nov; 10(22):2471-83. PubMed ID: 14529486
[TBL] [Abstract][Full Text] [Related]
4. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
5. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
Briones M; Bajaj M
Expert Opin Pharmacother; 2006 Jun; 7(8):1055-64. PubMed ID: 16722815
[TBL] [Abstract][Full Text] [Related]
6. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.
Drucker DJ
Curr Pharm Des; 2001 Sep; 7(14):1399-412. PubMed ID: 11472275
[TBL] [Abstract][Full Text] [Related]
7. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 and islet lipolysis.
Sörhede Winzell M; Ahrén B
Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.
Li Y; Hansotia T; Yusta B; Ris F; Halban PA; Drucker DJ
J Biol Chem; 2003 Jan; 278(1):471-8. PubMed ID: 12409292
[TBL] [Abstract][Full Text] [Related]
10. Incretin mimetics as emerging treatments for type 2 diabetes.
Joy SV; Rodgers PT; Scates AC
Ann Pharmacother; 2005 Jan; 39(1):110-8. PubMed ID: 15562141
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
Nauck MA; Meier JJ
Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
[TBL] [Abstract][Full Text] [Related]
12. Incretin hormones and insulin sensitivity.
Hansen PA; Corbett JA
Trends Endocrinol Metab; 2005; 16(4):135-6. PubMed ID: 15860408
[TBL] [Abstract][Full Text] [Related]
13. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.
Xu G; Stoffers DA; Habener JF; Bonner-Weir S
Diabetes; 1999 Dec; 48(12):2270-6. PubMed ID: 10580413
[TBL] [Abstract][Full Text] [Related]
14. Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats.
Kwon DY; Kim YS; Ahn IS; Kim DS; Kang S; Hong SM; Park S
J Pharmacol Sci; 2009 Dec; 111(4):361-71. PubMed ID: 20019445
[TBL] [Abstract][Full Text] [Related]
15. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
Tourrel C; Bailbe D; Lacorne M; Meile MJ; Kergoat M; Portha B
Diabetes; 2002 May; 51(5):1443-52. PubMed ID: 11978641
[TBL] [Abstract][Full Text] [Related]
16. Exenatide and weight loss.
Bradley DP; Kulstad R; Schoeller DA
Nutrition; 2010 Mar; 26(3):243-9. PubMed ID: 20152707
[TBL] [Abstract][Full Text] [Related]
17. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
Arakawa M; Ebato C; Mita T; Hirose T; Kawamori R; Fujitani Y; Watada H
Biochem Biophys Res Commun; 2009 Dec; 390(3):809-14. PubMed ID: 19836346
[TBL] [Abstract][Full Text] [Related]
18. Exenatide can reduce glucose independent of islet hormones or gastric emptying.
Ionut V; Zheng D; Stefanovski D; Bergman RN
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E269-77. PubMed ID: 18492781
[TBL] [Abstract][Full Text] [Related]
19. [Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist].
Zheng YC
Yao Xue Xue Bao; 2015 Dec; 50(12):1668-72. PubMed ID: 27169293
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of action of glucagon-like peptide 1 in the pancreas.
Doyle ME; Egan JM
Pharmacol Ther; 2007 Mar; 113(3):546-93. PubMed ID: 17306374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
